Blueprint Medicines (BPMC) Expected to Announce Quarterly Earnings on Thursday

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.44) per share and revenue of $158.31 million for the quarter.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, analysts expect Blueprint Medicines to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Blueprint Medicines Trading Down 0.5 %

Shares of NASDAQ:BPMC traded down $0.42 during midday trading on Tuesday, hitting $88.09. The company had a trading volume of 56,460 shares, compared to its average volume of 767,317. Blueprint Medicines has a 12 month low of $73.04 and a 12 month high of $121.90. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The stock has a market cap of $5.63 billion, a price-to-earnings ratio of -81.56 and a beta of 0.75. The firm has a fifty day simple moving average of $87.46 and a 200 day simple moving average of $93.18.

Insider Buying and Selling

In related news, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $95.02, for a total value of $216,075.48. Following the sale, the chief operating officer now owns 69,266 shares in the company, valued at approximately $6,581,655.32. This trade represents a 3.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Ariel Hurley sold 3,203 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the completion of the sale, the insider now owns 18,270 shares in the company, valued at $1,692,167.40. This trade represents a 14.92 % decrease in their position. The disclosure for this sale can be found here. 4.21% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

BPMC has been the subject of several recent analyst reports. Piper Sandler increased their price target on Blueprint Medicines from $109.00 to $119.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Needham & Company LLC reduced their price target on Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating for the company in a research report on Monday. Morgan Stanley assumed coverage on Blueprint Medicines in a report on Thursday, March 20th. They issued an "equal weight" rating and a $100.00 price objective for the company. JPMorgan Chase & Co. increased their price target on Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Finally, StockNews.com cut Blueprint Medicines from a "hold" rating to a "sell" rating in a research report on Monday, March 3rd. Two analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $124.53.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.